Drug intelligence / Profile preview

alpha-lipoic acid + insulin

Development stage: Unknown
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Oral, Subcutaneous

Overview

Alpha-lipoic acid + insulin is a combination therapy consisting of an antioxidant (alpha-lipoic acid) and a hormone medication (insulin). Alpha-lipoic acid works as an insulin sensitizer by improving glucose uptake via GLUT4 translocation and activation, while also providing antioxidant effects. When combined with insulin, it may enhance glycemic control but requires careful monitoring due to potential hypoglycemic effects.

Targets

INSR (Insulin receptor)AMPK (Adenosine monophosphate–activated protein kinase)SLC2A4 (Solute carrier family 2 facilitated glucose transporter member 4)

Beyond the preview

Go deeper on alpha-lipoic acid + insulin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on alpha-lipoic acid + insulin.

Explore the full profile